Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Tharimmune
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Public
Employees
3
Market Cap
$3.3M
Website
http://tharimmune.com
Clinical Trials
Related News
TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
Phase 2
Not yet recruiting
Conditions
Pruritus
Primary Biliary Cholangitis
Interventions
Drug: Nalmefene
Drug: Placebo
Subscribe
First Posted Date
2024-12-13
Last Posted Date
2024-12-17
Lead Sponsor
Tharimmune Inc
Target Recruit Count
40
Registration Number
NCT06733519
Subscribe
An Evaluation of The Absolute Bioavailability of TH104
Phase 1
Active, not recruiting
Conditions
Healthy
Interventions
Drug: Nalmefene
Subscribe
First Posted Date
2024-01-10
Last Posted Date
2024-02-13
Lead Sponsor
Tharimmune Inc
Target Recruit Count
20
Registration Number
NCT06198686
Locations
🇺🇸
Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy